Effects of MSC coadministration and route of delivery on cord blood hematopoietic stem cell engraftment

S. Carrancio, C. Romo, T. Ramos, N. Lopez-Holgado, S. Muntion, H. J. Prins, A. C. Martens, J. G. Briñón, J. F. San Migue, M. C. del Cañizo, F. Sanchez-Guijo

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Hematopoietic stem cell transplantation (HSCT) using umbilical cord blood (UCB) progenitors is increasingly being used. One of the problems that may arise after UCB transplantation is an impaired engraftment. Either intrabone (IB) injection of hematopoietic progenitors or mesenchymal stem cell (MSC) coadministration has been proposed among the strategies to improve engraftment. In the current study, we have assessed the effects of both approaches. Thus, NOD/SCID recipients were transplanted with human UCB CD34+ cells administered either intravenously (IV) or IB, receiving or not bone marrow (BM)-derived MSCs also IV or IB (in the right femur). Human HSC engraftment was measured 3 and 6 weeks after transplantation. Injected MSCs were tracked weekly by bioluminescence. Also, lodgment within the BM niche was assessed at the latter time point by immunofluorescence. Our study shows regarding HSC engraftment that the number of BM human CD45+ cells detected 3 weeks after transplantation was significantly higher in mice cotransplanted with human MSCs. Moreover, these mice had a higher myeloid (CD13+) engraftment and a faster B-cell (CD19+) chimerism. At the late time point evaluated (6 weeks), human engraftment was higher in the group in which both strategies were employed (IB injection of HSC and MSC coadministration). When assessing human MSC administration route, we were able to track MSCs only in the injected femurs, whereas they lost their signal in the contralateral bones. These human MSCs were mainly located around blood vessels in the subendosteal region. In summary, our study shows that MSC coadministration can enhance HSC engraftment in our xenogenic transplantation model, as well as IB administration of the CD34+ cells does. The combination of both strategies seems to be synergistic. Interestingly, MSCs were detected only where they were IB injected contributing to the vascular niche.

Original languageEnglish
Pages (from-to)1171-1183
Number of pages13
JournalCell Transplantation
Volume22
Issue number7
DOIs
Publication statusPublished - 5 Jul 2013

Cite this

Carrancio, S., Romo, C., Ramos, T., Lopez-Holgado, N., Muntion, S., Prins, H. J., ... Sanchez-Guijo, F. (2013). Effects of MSC coadministration and route of delivery on cord blood hematopoietic stem cell engraftment. Cell Transplantation, 22(7), 1171-1183. https://doi.org/10.3727/096368912X657431
Carrancio, S. ; Romo, C. ; Ramos, T. ; Lopez-Holgado, N. ; Muntion, S. ; Prins, H. J. ; Martens, A. C. ; Briñón, J. G. ; San Migue, J. F. ; del Cañizo, M. C. ; Sanchez-Guijo, F. / Effects of MSC coadministration and route of delivery on cord blood hematopoietic stem cell engraftment. In: Cell Transplantation. 2013 ; Vol. 22, No. 7. pp. 1171-1183.
@article{90eb0ad9210d46a090d2b3cc7e59f41f,
title = "Effects of MSC coadministration and route of delivery on cord blood hematopoietic stem cell engraftment",
abstract = "Hematopoietic stem cell transplantation (HSCT) using umbilical cord blood (UCB) progenitors is increasingly being used. One of the problems that may arise after UCB transplantation is an impaired engraftment. Either intrabone (IB) injection of hematopoietic progenitors or mesenchymal stem cell (MSC) coadministration has been proposed among the strategies to improve engraftment. In the current study, we have assessed the effects of both approaches. Thus, NOD/SCID recipients were transplanted with human UCB CD34+ cells administered either intravenously (IV) or IB, receiving or not bone marrow (BM)-derived MSCs also IV or IB (in the right femur). Human HSC engraftment was measured 3 and 6 weeks after transplantation. Injected MSCs were tracked weekly by bioluminescence. Also, lodgment within the BM niche was assessed at the latter time point by immunofluorescence. Our study shows regarding HSC engraftment that the number of BM human CD45+ cells detected 3 weeks after transplantation was significantly higher in mice cotransplanted with human MSCs. Moreover, these mice had a higher myeloid (CD13+) engraftment and a faster B-cell (CD19+) chimerism. At the late time point evaluated (6 weeks), human engraftment was higher in the group in which both strategies were employed (IB injection of HSC and MSC coadministration). When assessing human MSC administration route, we were able to track MSCs only in the injected femurs, whereas they lost their signal in the contralateral bones. These human MSCs were mainly located around blood vessels in the subendosteal region. In summary, our study shows that MSC coadministration can enhance HSC engraftment in our xenogenic transplantation model, as well as IB administration of the CD34+ cells does. The combination of both strategies seems to be synergistic. Interestingly, MSCs were detected only where they were IB injected contributing to the vascular niche.",
keywords = "Bone marrow microenvironment, Cordon blood transplantation, Hematopoietic engraftment, Mesenchymal stem cells (MSCs)",
author = "S. Carrancio and C. Romo and T. Ramos and N. Lopez-Holgado and S. Muntion and Prins, {H. J.} and Martens, {A. C.} and Bri{\~n}{\'o}n, {J. G.} and {San Migue}, {J. F.} and {del Ca{\~n}izo}, {M. C.} and F. Sanchez-Guijo",
year = "2013",
month = "7",
day = "5",
doi = "10.3727/096368912X657431",
language = "English",
volume = "22",
pages = "1171--1183",
journal = "Cell Transplantation",
issn = "0963-6897",
publisher = "Cognizant Communication Corporation",
number = "7",

}

Carrancio, S, Romo, C, Ramos, T, Lopez-Holgado, N, Muntion, S, Prins, HJ, Martens, AC, Briñón, JG, San Migue, JF, del Cañizo, MC & Sanchez-Guijo, F 2013, 'Effects of MSC coadministration and route of delivery on cord blood hematopoietic stem cell engraftment' Cell Transplantation, vol. 22, no. 7, pp. 1171-1183. https://doi.org/10.3727/096368912X657431

Effects of MSC coadministration and route of delivery on cord blood hematopoietic stem cell engraftment. / Carrancio, S.; Romo, C.; Ramos, T.; Lopez-Holgado, N.; Muntion, S.; Prins, H. J.; Martens, A. C.; Briñón, J. G.; San Migue, J. F.; del Cañizo, M. C.; Sanchez-Guijo, F.

In: Cell Transplantation, Vol. 22, No. 7, 05.07.2013, p. 1171-1183.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Effects of MSC coadministration and route of delivery on cord blood hematopoietic stem cell engraftment

AU - Carrancio, S.

AU - Romo, C.

AU - Ramos, T.

AU - Lopez-Holgado, N.

AU - Muntion, S.

AU - Prins, H. J.

AU - Martens, A. C.

AU - Briñón, J. G.

AU - San Migue, J. F.

AU - del Cañizo, M. C.

AU - Sanchez-Guijo, F.

PY - 2013/7/5

Y1 - 2013/7/5

N2 - Hematopoietic stem cell transplantation (HSCT) using umbilical cord blood (UCB) progenitors is increasingly being used. One of the problems that may arise after UCB transplantation is an impaired engraftment. Either intrabone (IB) injection of hematopoietic progenitors or mesenchymal stem cell (MSC) coadministration has been proposed among the strategies to improve engraftment. In the current study, we have assessed the effects of both approaches. Thus, NOD/SCID recipients were transplanted with human UCB CD34+ cells administered either intravenously (IV) or IB, receiving or not bone marrow (BM)-derived MSCs also IV or IB (in the right femur). Human HSC engraftment was measured 3 and 6 weeks after transplantation. Injected MSCs were tracked weekly by bioluminescence. Also, lodgment within the BM niche was assessed at the latter time point by immunofluorescence. Our study shows regarding HSC engraftment that the number of BM human CD45+ cells detected 3 weeks after transplantation was significantly higher in mice cotransplanted with human MSCs. Moreover, these mice had a higher myeloid (CD13+) engraftment and a faster B-cell (CD19+) chimerism. At the late time point evaluated (6 weeks), human engraftment was higher in the group in which both strategies were employed (IB injection of HSC and MSC coadministration). When assessing human MSC administration route, we were able to track MSCs only in the injected femurs, whereas they lost their signal in the contralateral bones. These human MSCs were mainly located around blood vessels in the subendosteal region. In summary, our study shows that MSC coadministration can enhance HSC engraftment in our xenogenic transplantation model, as well as IB administration of the CD34+ cells does. The combination of both strategies seems to be synergistic. Interestingly, MSCs were detected only where they were IB injected contributing to the vascular niche.

AB - Hematopoietic stem cell transplantation (HSCT) using umbilical cord blood (UCB) progenitors is increasingly being used. One of the problems that may arise after UCB transplantation is an impaired engraftment. Either intrabone (IB) injection of hematopoietic progenitors or mesenchymal stem cell (MSC) coadministration has been proposed among the strategies to improve engraftment. In the current study, we have assessed the effects of both approaches. Thus, NOD/SCID recipients were transplanted with human UCB CD34+ cells administered either intravenously (IV) or IB, receiving or not bone marrow (BM)-derived MSCs also IV or IB (in the right femur). Human HSC engraftment was measured 3 and 6 weeks after transplantation. Injected MSCs were tracked weekly by bioluminescence. Also, lodgment within the BM niche was assessed at the latter time point by immunofluorescence. Our study shows regarding HSC engraftment that the number of BM human CD45+ cells detected 3 weeks after transplantation was significantly higher in mice cotransplanted with human MSCs. Moreover, these mice had a higher myeloid (CD13+) engraftment and a faster B-cell (CD19+) chimerism. At the late time point evaluated (6 weeks), human engraftment was higher in the group in which both strategies were employed (IB injection of HSC and MSC coadministration). When assessing human MSC administration route, we were able to track MSCs only in the injected femurs, whereas they lost their signal in the contralateral bones. These human MSCs were mainly located around blood vessels in the subendosteal region. In summary, our study shows that MSC coadministration can enhance HSC engraftment in our xenogenic transplantation model, as well as IB administration of the CD34+ cells does. The combination of both strategies seems to be synergistic. Interestingly, MSCs were detected only where they were IB injected contributing to the vascular niche.

KW - Bone marrow microenvironment

KW - Cordon blood transplantation

KW - Hematopoietic engraftment

KW - Mesenchymal stem cells (MSCs)

UR - http://www.scopus.com/inward/record.url?scp=84879560059&partnerID=8YFLogxK

U2 - 10.3727/096368912X657431

DO - 10.3727/096368912X657431

M3 - Article

VL - 22

SP - 1171

EP - 1183

JO - Cell Transplantation

JF - Cell Transplantation

SN - 0963-6897

IS - 7

ER -